The overall 5-year survival rate for melanoma is high compared to many cancers, largely because most cases are caught early. When melanoma is still confined to the skin where it started, the 5-year relative survival rate is greater than 99%. That number drops significantly once the cancer spreads, which is why stage at diagnosis matters more than almost any other factor. An estimated 112,000 new cases will be diagnosed in 2026, with roughly 8,510 deaths.
Survival Rates by Stage
Melanoma survival is reported using three broad categories based on how far the cancer has spread at the time of diagnosis. These figures, from the American Cancer Society using data collected between 2015 and 2021, represent relative survival, meaning they compare melanoma patients to the general population and filter out other causes of death.
- Localized (stages I and II): Greater than 99% five-year survival. The cancer has not spread beyond the original site in the skin.
- Regional (stage III): 76% five-year survival. The cancer has reached nearby lymph nodes or surrounding tissue.
- Distant (stage IV): 35% five-year survival. The cancer has spread to distant organs like the lungs, liver, or brain.
The good news is that the majority of melanomas are diagnosed at the localized stage. These numbers also reflect real improvement. Older datasets showed regional survival closer to 60% and distant survival around 16%, so the gains over the past decade have been substantial.
How Tumor Thickness Affects Outlook
Within localized melanoma, not all tumors carry the same risk. The single most important measurement is Breslow thickness, which is how deep the melanoma has grown into the skin, measured in millimeters under a microscope after a biopsy.
- Less than 1 mm: 95 to 100% five-year survival
- 1 to 2 mm: 80 to 96%
- 2.1 to 4 mm: 60 to 75%
- Greater than 4 mm: 37 to 50%
This is why early detection changes the equation so dramatically. A melanoma caught at less than a millimeter deep is essentially curable with surgery alone. Once it grows past 4 mm, the risk of it having already spread, even if imaging doesn’t show it yet, rises sharply. The wide ranges in each category reflect other factors like whether the tumor’s surface has broken down (ulceration) and how quickly the cells are dividing.
Where on the Body Matters
The location of a melanoma on your body carries its own prognostic weight. A large study using the national SEER database found that melanomas on the head and neck are associated with higher mortality compared to those on the trunk, even after adjusting for thickness and stage. Melanomas on the arms and legs tend to have slightly better outcomes than trunk melanomas. The reasons likely involve differences in how quickly tumors at each site reach nearby lymph nodes and how readily they’re noticed.
Lymph Node Status Is Not Always Decisive
Whether cancer cells have reached nearby lymph nodes has traditionally been considered one of the strongest predictors of outcome. A procedure called sentinel lymph node biopsy checks for this by examining the first lymph node that drains from the tumor site. But the relationship between lymph node involvement and survival is more nuanced than it might seem.
Patients with thick primary tumors (stages IIB and IIC) who test negative for lymph node involvement can actually have similar survival rates to patients with thinner tumors that have spread to lymph nodes (stages IIIA and IIIB). This suggests the characteristics of the primary tumor itself, particularly its thickness and whether it’s ulcerated, carry as much or more prognostic weight as early lymph node spread. Younger patients are more likely to have a positive lymph node biopsy but paradoxically face lower melanoma mortality than older patients with the same finding.
How Immunotherapy Changed Stage III and IV Outcomes
The survival landscape for advanced melanoma has shifted dramatically since checkpoint inhibitor immunotherapy became standard treatment. These drugs work by removing the brakes that cancer cells place on the immune system, allowing the body to attack the tumor.
For patients diagnosed with stage III or IV melanoma, five-year overall survival rose from 41% in the pre-immunotherapy era to 60% in the immunotherapy era. The improvement was seen across both stages. For stage III, five-year survival went from 55% to 67%, and median overall survival extended from about 83 months to a point where the median had not yet been reached, meaning more than half of patients were still alive at the end of follow-up. For stage IV specifically, the picture changed even more starkly: median survival doubled from 8.3 months to 15.2 months, and five-year survival climbed from 14% to 31%.
These gains are real but not equally distributed. The same research documented persistent disparities by race and socioeconomic status, with underserved populations seeing smaller improvements.
Long-Term Recurrence Risk
Even after successful treatment, melanoma can come back years later. In two large study cohorts of patients with stage I and II melanoma, recurrence rates ranged from about 9% to 14%. The ten-year recurrence-free survival varied considerably by substage:
- Stage IA: 88 to 91% remained recurrence-free at 10 years
- Stage IB: 79 to 80%
- Stage IIA: 62 to 64%
- Stage IIB: 55%
- Stage IIC: 33 to 49%
One important detail: a substantial number of recurrences and melanoma-related deaths happen more than five years after the initial surgery. This is why follow-up surveillance typically continues well beyond the standard five-year mark. Melanoma is not a cancer where you can assume you’re in the clear simply because the first five years have passed, particularly with thicker tumors. Regular skin checks and monitoring for new symptoms remain important for years, and in many cases, indefinitely.